Treatment of Glabellar Lines with Daxxify May Improve Skin Smoothness: Analysis
A new study suggests optimization of aesthetic outcomes when treating glabellar lines with Daxxify® (daxibotulinumtoxinA for injection) may improve skin smoothness in addition to wrinkle severity.
The study, designed as a quantitative image analysis, included 61 enrolled patients, 60 of whom where eligible for analysis (88.3% female). Patients were assigned to one of 5 groups based on skin texture score at baseline. Participants were also photographed at baseline and again at Week 2 after 40U of treatment with Daxxify.
Over 90% of the subjects with the least smooth skin at baseline (Group 5 in the study) saw improvement in skin texture at Week 2. The degree of improvement in skin texture was highly correlated with baseline skin texture score (r=0.46; P=0.0002), according to the study researchers.
"We found something really interesting," said Shannon Humphrey, MD, a dermatologist in private practice in Vancouver, said in an oral abstract presentation. "When we divided the participants between their baseline skin texture with Group 1 having the best skin texture, and Group 5 having the worst, we actually see the greatest degree of improvement, perhaps not surprisingly, in patients whose skin was not smooth at baseline. It's actually an inverse correlation, so the worse the texture was at the beginning, the greater the degree of improvement at two-week follow-up."
The study results, presented for the first time in a an oral abstract presentation at the American Society for Dermatologic Surgery (ASDS) 2023 Annual Membership Meeting in Chicago,
"As a clinician scientist is that this really helps explain what I saw in the studies in my patients," Dr. Humphreys added. "Not only did they have excellent improvement in skin quality that now we've been able to show in this novel study was also quantitative."
Disclosures
Dr. Humphreys has served as a speaker, consultant, and/or investigator for Allergan, Galderma, Medytox, and Revance.
Dr. Comstock has served as a speaker and/or consultant for Allergan, Galderma and Revance, and has served as Cosmetic Medical Director for skinbetter science®.
Drs. Brown, Stephenson, Kooken and Sparrow are employees and stockholders of Revance Therapeutics, Inc.
Writing and editorial assistance for the study was funded by Revance Therapeutics,Inc.
Reference
Humphrey S, Comstock J, Brown J, Stephenson J, Kooken K, Sparrow J. Treatment of glabellar lines with daxibotulinumtoxinA may improve skin smoothness. Oral abstract. Presented at: American Society for Dermatologic Surgery (ASDS) 2023 Annual Membership Meeting. November 2-5, 2023, Chicago.